Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis

NCT05070858 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.

NCT NCT05070858
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05070858 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis
Lead sponsor
Regeneron Pharmaceuticals
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 14, 2021
Completion date
November 11, 2028
Enrollment
288 (actual)
Sites
116

Conditions

As the registry lists them; a condition with its own page is linked.

generalized myasthenia gravis